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Abstract 24 
Streptococcus suis is a bacterium commonly carried in the respiratory tract that is also 25 
one of the most important invasive pathogens of swine, commonly causing meningitis, arthritis, 26 
and septicemia. Due to the existence of many serotypes and a wide range of immune evasion 27 
capabilities efficacious vaccines are not readily available. The selection of S. suis protein 28 
candidates for inclusion in a vaccine was accomplished by identifying fitness genes through a 29 
functional genomics screen and selecting conserved predicted surface-associated proteins. Five 30 
candidate proteins were selected for evaluation in a vaccine trial and administered both 31 
intranasally and intramuscularly with one of two different adjuvant formulations. Clinical 32 
protection was evaluated by subsequent intranasal challenge with virulent S. suis. While subunit 33 
vaccination with the S. suis proteins induced IgG antibody titers to each individual protein, a 34 
cellular immune response to the pool of proteins, and provided substantial protection from 35 
challenge with virulent S. suis, the immune response elicited and degree of protection were 36 
dependent on the parenteral adjuvant given. Subunit vaccination induced IgG reactive against 37 
different S. suis serotypes indicating a potential for cross-protection.  38 
 39 
Introduction 40 
Streptococcus suis is a Gram-positive bacterium commonly carried in the tonsil and nasal 41 
cavity of swine that can cause systemic disease and secondary pneumonia, especially in young 42 
pigs. Streptococcal disease is widespread wherever pig production occurs and systemic invasion 43 
most commonly results in septicemia, meningitis, arthritis, and/or polyserositis causing 44 
significant economic losses to the industry. S. suis is also a zoonotic agent capable of causing 45 
meningitis in humans, and although historically sporadic in nature, there have been recent larger 46 
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outbreaks in China and Vietnam with high levels of mortality (1-3). There are at least 33 47 
capsular serotypes (1-31, 33 and 1/2) of S. suis, with serotypes 32 and 34 reassigned (4), and 48 
ongoing controversy over the appropriate speciation of serotypes 20, 22, 26, and 33 (5). In most 49 
countries, capsular serotype 2 is the most virulent and the most frequently isolated from both 50 
diseased swine and humans (6). However, depending on geographic location other serotypes 51 
such as 1, 1/2, 3, 7, 8, 9, 14 are commonly isolated from diseased pigs (7-10). 52 
The mechanisms that enable S. suis to invade systemically from the respiratory tract are 53 
not well understood, though numerous potential virulence factors or virulence-related factors 54 
have been identified (reviewed in Segura et al.) (11). However, none of these factors appear 55 
individually to correlate completely with the ability to cause disease and thus virulence is 56 
probably multifactorial, and, to date, no highly effective vaccines have been developed to protect 57 
against S. suis disease. Genomic analysis of large numbers of isolates with known commensal or 58 
disease-associated provenance revealed a complex population structure with high levels of 59 
recombination and marked genomic differences between the two groups (12). The presence of 60 
multiple serotypes and high genotypic variability may make it difficult to develop broadly 61 
protective vaccines. 62 
A relatively new technique called TraDIS (Transposon Directed Insertion Sequencing) or 63 
TnSeq is a method used to simultaneously identify bacterial fitness genes by the generation of a 64 
random transposon library disrupting individual gene expression and assessment of the effects of 65 
the disruption on survivability under selection conditions. High throughput sequencing 66 
technology is used to generate sequence reads spanning the transposon/chromosome boundaries 67 
of each insertion, allowing for the en masse accurate mapping of transposon insertion sites (13-68 
17). By identifying members of the library that are no longer present after the applied negative 69 
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selection, disrupted genes that are important for fitness under the applied conditions can be 70 
readily identified. Prior to this study we processed a strain P1/7 S. suis TraDIS library through an 71 
in vitro organ culture system (IVOC) using pig nasal epithelium to select genes encoding 72 
proteins that may be involved in colonization fitness. Using in silico bioinformatics approaches 73 
five S. suis proteins were further selected on the basis of likely cell surface location and 74 
conservation. The five proteins were cloned, expressed and purified in Escherichia coli and then 75 
tested as potential vaccine candidates in swine.  76 
 77 
Results 78 
Characteristics of the five candidate vaccine proteins. Five candidate vaccine proteins 79 
(SSU0185, SSU1215, SSU1355, SSU1773, SSU1915) were selected based on the results of the 80 
experimental functional genomics screening and in silico bioinformatics approaches described in 81 
the Materials and Methods section (Table 1). Candidates with a significant reduction in fitness of 82 
transposon mutants in IVOC with swine respiratory epithelium were narrowed down to genes 83 
encoding surface-associated proteins excluding those containing trans-membrane domains in the 84 
middle of protein coding sequence (Table 1). Homology searches were used to identify proteins 85 
highly conserved in 459 publically available S. suis genomes which cover all serotypes with the 86 
exception of 20, 22 and 33 and come from Argentina, Canada, China, Denmark, Germany, The 87 
Netherlands, United Kingdom and Vietnam (Table 2 and 3). Of the five proteins chosen, 88 
SSU0185 and SSU1355 were found in the genome of all 459 S. suis isolates, SSU1915 was 89 
found in >99% of the isolates, and SSU1215 and SSU1773 were found in >98%, of the isolates 90 
(Table 2). Protein identities of the five subunit vaccine candidates were compared to S. suis 91 
strains with complete genomes in GenBank (Table S1) and disease-associated S. suis serotype 92 
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representatives from the 459 S. suis genome collection (Table 3). These strains represent disease-93 
associated S. suis serotypes isolated from diverse global geographic sources.  Overall, the five 94 
candidate proteins had >91% protein identities in these strains compared to those in P1/7. The 95 
immunoreactivity of the recombinant proteins was tested with serum, collected from a 96 
convalescent pig infected with a serotype 2 S. suis strain under experimental conditions, in a 97 
Western blot (Figure 1). Reactivity to four of the proteins (SSU1215, SSU1355, SSU1773, and 98 
SSU1915) was observed. The potential to apply the five candidate proteins as a pool of subunit 99 
vaccines has not been previously published, patented or tested in pig protection studies. 100 
Parenteral adjuvant formulation and boosting significantly impacts the serum IgG 101 
S. suis protein specific response. Two groups of pigs were vaccinated with the five proteins 102 
both intranasally with Polyethyleneimine as adjuvant and intramuscularly with one of two 103 
adjuvant combinations, AddaVax
/
Carbopol (group 1) or Emulsigen-D (group 2) as described in 104 
the Materials and Methods section (Table 4). Groups 3-5 were control groups given PBS mixed 105 
with the same adjuvants given to groups 1 and 2 or PBS only, respectively. Overall, serum IgG 106 
antibody reactive against all five proteins was detected in all vaccinated pigs, and there was an 107 
anamnestic response after administration of the boost vaccination (Figure 2). No S. suis protein-108 
specific IgG was detected in the pigs given adjuvant alone or PBS (data not shown), nor was 109 
there a response detected in serum collected at day 0. Two weeks following priming (day 14), 110 
IgG titers specific to individual S. suis proteins were significantly higher in serum from pigs in 111 
group 2 (Emulsigen-D adjuvant) compared to group 1 (Carbopol/AddaVax adjuvant) and this 112 
trend continued after the response was boosted (day 21 and 28). In fact, IgG titers to the proteins 113 
in group 2 pigs after a single injection were approximately equal to the titers in group 1 pigs after 114 
2 injections. 115 
 o
n
 January 29, 2018 by LO
NDO
N SCHO
O
L O
F HYG
IENE & TRO
PICAL M
ED
http://iai.asm
.org/
D
ow
nloaded from
 
                                                                                                                                                     6 
 
Peripheral S. suis protein-specific IFN-γ recall response declines following boost 116 
immunization. The number of PBMCs producing IFN-γ following re-exposure to the pool of S. 117 
suis proteins was used as a measure of vaccine-induced cell-mediated immunity. The number of 118 
IFN-γ secreting cells (SC) following re-stimulation with S. suis proteins was greatest on day 14 119 
post-priming, and adjuvant formulation had a significant impact on responses with pigs in group 120 
2 (Emulsigen-D adjuvant) having significantly higher numbers of IFN-γ SC compared to group 1 121 
(Carbopol/AddaVax adjuvant)  (Figure 3). The number of IFN-γ SC detected decreased over 122 
time; with an average of 263 and 32 IFN-γ SC for group 2 detected on days 14 and 28, 123 
respectively. PBMC collected from pigs in groups 3, 4 and 5 (no antigen groups) did not have 124 
more than 13 IFN-γ SC detected at any time point following stimulation S. suis proteins. In 125 
addition, the number of IFN-γ SC detected following stimulation with media alone remained 126 
below 10 at each time point evaluated. While there was, on average, an increase in the number of 127 
IFN-γ SC using PBMC from pigs in group 1 at day 14 post-priming, it was not significantly 128 
increased over control groups (groups 3-5). 129 
Cytokines produced by PBMCs following restimulation with the protein pool were 130 
highest in pigs vaccinated with Emulsigen-D adjuvant. PBMCs collected on day 28, 2 weeks 131 
after boost vaccination, were stimulated with the pool of five S. suis proteins as another measure 132 
of vaccine-induced cell-mediated immunity. Overall, cytokines produced by PBMCs following 133 
restimulation with the protein pool were highest in pigs from group 2 (Emulsigen-D adjuvant) 134 
(Figure 4). These levels were statistically higher for group 2 compared to all other groups for IL-135 
2 and TNF-α, whereas there was no statistical difference in the amount of these cytokines 136 
produced among groups 1 (Carbopol/AddaVax adjuvant) and 3-5 (control groups). 137 
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Subunit vaccination provides significant protection against lethal challenge with S. 138 
suis and is associated with the immune response and adjuvant given. Following virulent 139 
challenge, nine out of ten pigs in non-vaccinated control groups 3-5 developed severe signs of 140 
systemic S. suis infection (lameness with swollen joints, anorexia, depression, dyspnea, and 141 
neurologic signs) and had to be euthanized (Figure 5). S. suis was cultured from systemic sites of 142 
these 9 pigs including serosa (5/9), joint (9/9), CSF (9/9), and spleen (8/9), and macroscopic and 143 
microscopic lesions consistent with S. suis infection including meningitis, polyserositis and 144 
arthritis were present. S. suis was readily isolated from the nasal cavity and tonsil of these pigs as 145 
well, but only small numbers of S. suis were isolated from the lung lavage of 5 of them, and 146 
pneumonia was not a prominent lesion that was seen. There was one pig in group 5 that only 147 
developed intermittent mild lameness beginning 1 day after challenge that continued throughout 148 
the observation period but demonstrated no other clinical signs, and S. suis was only isolated 149 
from the nasal wash and tonsil of this pig at the termination of the experiment on day 15.  150 
By comparison, the two vaccinated groups had 3/6 pigs in group 1 (Carbopol/AddaVax 151 
adjuvant) and only 1/6 pigs in group 2 (Emulsigen-D adjuvant) develop severe systemic disease 152 
requiring euthanasia (Figure 5). Survival was significantly greater for group 2 compared to the 153 
combined non-immunized control groups. Similar to the control groups S. suis was isolated from 154 
systemic sites (4/4 serosa, 4/4 joint, 3/4 CSF, and 3/4 spleen) of the four pigs in the vaccinated 155 
groups that had to be euthanized and macroscopic and microscopic lesions consistent with S. suis 156 
infection were present. The nasal cavity and tonsil were heavily colonized in all the vaccinated 157 
pigs, but virtually no S. suis was isolated from the lung lavage from any of these pigs. One pig 158 
from group 2 was lame for two days with no other clinical signs and recovered uneventfully, and 159 
S. suis was only isolated from the nasal wash and tonsil but no systemic site of this pig, and no 160 
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macroscopic or microscopic lesions consistent with S. suis infection were present at the end of 161 
the experiment when all the remaining pigs were euthanized. In addition, S. suis was isolated 162 
from the spleen from one pig in each of group 1 and 2 that appeared clinically healthy 163 
throughout the experiment. Neither of these pigs had any macroscopic or microscopic lesions 164 
consistent with S. suis infection. 165 
Subunit vaccination induces IgG reactive against whole S. suis bacteria. An indirect 166 
ELISA was performed to determine if serum IgG from vaccinated pigs collected on day 28 post-167 
vaccination reacted with whole P1/7 S. suis bacteria or other S. suis isolates representing 168 
serotypes commonly associated with disease (serotypes 1, 2, 1-2, 3 and 14). Although there were 169 
some differences in the degree of reactivity across the different isolates, there was an appreciable 170 
IgG response to all S. suis isolates tested, indicating a considerable amount of reactivity to 171 
different isolates of S. suis, which vary in respect to serotypes (Figure 6). As with the other 172 
measured immune parameters, the S. suis-specific IgG response induced in group 2 (Emulsigen-173 
D adjuvant) pigs was higher than that in group 1 (Carbopol/AddaVax adjuvant). 174 
 175 
Discussion 176 
The five S. suis proteins in this study were chosen based on first determining 177 
genes/proteins that were predicted to play a role in fitness during colonization of the respiratory 178 
tract, the initial stage in establishing infection, using a respiratory epithelium IVOC system and 179 
transposon mutant library. The identified proteins are predicted to have functions in several 180 
physiological processes, in particular those associated with metabolism and nutrient acquisition, 181 
which might explain their role in survival on respiratory epithelium.  182 
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SSU0185 was identified as a putative tagatose-6-phosphate aldose/ketose isomerase. The 183 
ortholog of this protein, AgaS, is believed to be part of the pathway for utilization of the amino 184 
sugar, N-acetyl-D-galactosamine in E. coli (18). The abundance of free sugars is scarce in the 185 
respiratory tract and mucins, a major component of the mucus produced by respiratory surfaces, 186 
contain glycoproteins composed of sugars, amino sugars, and sulphated sugars commonly linked 187 
to a protein core via an N-acetylgalactosamine (19). Orthologs of agaS have been identified in 188 
other Streptococcus species, such as Streptococcus pneumoniae, where it was shown to be 189 
upregulated upon exposure to human macrophage-like cells and when grown in the presence of 190 
mucin, potentially explaining the importance of this protein for survival in the respiratory tract 191 
(20, 21). 192 
SSU1915 was identified as a putative maltose/maltodextrin-binding protein whose 193 
ortholog is MalX, a lipid-anchored solute binding protein of an ATP binding cassette (ABC)-194 
transporter. MalX has been reported as a streptococcal virulence factor involved in carbohydrate 195 
metabolism, specifically in polysaccharide degradation and synthesis (22). Members of the mal 196 
regulon of Streptococcus pyogenes have been shown to enhance colonization of the oropharynx 197 
through their niche-specific role in the utilization of dietary starch (23-25). Another study 198 
identified malX of S. pneumoniae as one of the niche-specific virulence genes upregulated in the 199 
lung and confirmed attenuation of virulence of a malX mutant during lung infection (26).  In the 200 
same report, vaccination with MalX induced high antibody titers but not significant protection in 201 
an intraperitoneal challenge model (26). In contrast, Moffitt et al. demonstrated that intranasal 202 
vaccination with the S. pneumoniae protein SP2108, the MalX ortholog, was protective in a 203 
mouse model of pneumococcal nasopharyngeal colonization (27). Subsequently they established 204 
that the lipid modification of this protein is critical to its immunogenicity in a TLR2-dependent 205 
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manner, and there was an in trans effect of the lipoprotein that enhanced the immunogenicity of 206 
a co-administered nonlipidated antigen (28).  207 
SSU1355 was identified as a putative surface-anchored 5'-nucleotidase, a hydrolytic 208 
enzyme that catalyzes the hydrolysis of a nucleotide into a nucleoside and a phosphate. These 209 
enzymes have been identified as virulence factors, purportedly by hydrolyzing extracellular 210 
nucleotides for purine salvage, degrading nucleotide diphosphate sugars that can then be used by 211 
the cell, and/or by generating extracellular adenosine in the host, which is a powerful 212 
immunosuppressant signaling molecule. Staphylococcus aureus produces extracellular adenosine 213 
to evade clearance by the host immune system, an activity attributed to the 5'-nucleotidase 214 
activity of adenosine synthase (AdsA) (29).  215 
SSU1215 was identified as a putative surface-anchored dipeptidase. These enzymes play 216 
roles in several physiologic processes, such as catabolism of exogenously supplied peptides and 217 
the final steps of protein turnover.  218 
SS1773 was identified as a putative surface-anchored serine protease. Prokaryotic serine 219 
proteases have roles in several physiological processes, such as those associated with 220 
metabolism, cell signaling, and defense response and development; however, functional 221 
associations for a large number of prokaryotic serine proteases are relatively unknown.  222 
Since the methods used to identify these proteins indicated they were involved in 223 
respiratory colonization fitness, there was the possibility that locally induced mucosal or 224 
parenterally induced systemic immune responses, or both, would be important for protection. 225 
Since raising CDCD pigs is not a trivial matter and S. suis infection can have severe clinical 226 
consequences, it was decided to vaccinate with all five proteins by both routes to enhance the 227 
potential for success using the fewest number of pigs initially. Subsequently, further experiments 228 
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could be conducted to determine the role of each of the proteins and the role of the route of 229 
delivery in protection, and test protection against a heterologous challenge. Polyethyleneimine, 230 
an organic polycation, was chosen as the adjuvant for intransal vaccination because it has 231 
previously been shown to be a potent mucosal adjuvant for delivery antigens of mucosal 232 
pathogens (30, 31). We chose a combination of Addavax
TM
,  a squalene-based oil-in-water 233 
adjuvant similar to MF-59
®
 used in human influenza vaccines in Europe, and Carbopol
®
-971, a 234 
polyanionic carbomer as one choice for parenteral adjuvant based on previous work 235 
demonstrating this type of combination yielded an additive or potentially synergistic adjuvant 236 
effect (32). In addition, we chose Emulsigen
®
-D, an oil-in-water emulsion with 237 
dimethyldioctadecylammonium bromide as the second parenteral adjuvant, which has also been 238 
shown to induce enhanced immune responses compared to some commonly used adjuvants (33). 239 
Both the magnitude of the systemic immune response and degree of protection was dependent on 240 
the parenteral adjuvant administered with the proteins. This would suggest that parenteral 241 
vaccination was the important delivery method for protection; however, a role for mucosal 242 
immunization in protection or priming of the immune response cannot be ruled out, and 243 
additional studies separating the routes of administration will be needed to determine these roles.  244 
Even though the proteins were identified as potentially contributing to fitness for 245 
respiratory colonization, all surviving vaccinated animals showed tonsil and nasal colonization 246 
by the challenge organism. A quantitative comparison of colonizing bacterial load for 247 
immunized versus non-immunized animals was beyond the scope of this preliminary study, so 248 
there could have been a reduction of numbers of S. suis colonizing the respiratory sites that was 249 
not detected. In addition, since mucosal IgA was not measured it is difficult to state whether 250 
there was a failure of induction of mucosal antibodies to these proteins or a failure of antibodies 251 
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to prevent colonization. The impact of immunization on reduction of colonization load by 252 
pneumococcus in a mouse model was found to be dependent on individual host as well vaccine 253 
associated factors (34). There was a reduction of systemic disease in vaccinated animals, which 254 
could be due to reduced colonization and invasion or an increase in bactericidal/opsonic 255 
antibodies, or both. Streptococcus suis was also isolated from the spleen of two apparently 256 
healthy vaccinated pigs. These animals probably had an ongoing bacteremia that was being 257 
controlled and cleared by the immune response since, as indicated, the animals showed no 258 
antemortem, post mortem or histopathological signs of streptococcal disease. It is possible that 259 
this represented a very recent bacteremia; however, in our infection model with this strain of S. 260 
suis, we rarely have pigs develop or succumb to disease past day 10 of exposure. 261 
Peripheral IFN-γ recall responses were evaluated at various time points after vaccination, 262 
and there was a reduction in the number of peripheral S. suis-specific IFN-γ SC after the boost 263 
(Figure 3). However, there was an increase in peripheral S. suis-specific IgG levels after the 264 
second dose of vaccine, indicating a boost in immune responses following the second dosing. 265 
While the reduction in IFN-γ SC was somewhat unexpected, it is important to note that IFN-γ SC 266 
serve as a single measure of immune cell activation, and cell-mediated immune responses after 267 
prime-boost were likely skewed towards T-helper responses not involving IFN-γ production. 268 
Given the increased levels of S. suis-specific IgG after the boost, T cell responses were likely 269 
directed towards B-cell affinity maturation and plasma cell generation, which would include 270 
production of IL-13 and IL-5, though levels of these cytokines were not measured in this study. 271 
Overall, subunit vaccination with the five S. suis proteins induced an immune response that 272 
provided substantial protection from lethal challenge with virulent S. suis, and specifics on the 273 
mechanism of protection warrant further investigation.  274 
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S. suis is a diverse species of multiple serotypes, each represented by immunologically 275 
different capsule types, and displaying a wide range of immune-evading features that, to date, 276 
has challenged the development of efficacious vaccines (35). In particular, although opsonizing 277 
antibody is believed to be key to S. suis killing in infected animals (36), the antibody response to 278 
S. suis capsule has been shown to be limited in infected animals (37). Although much effort has 279 
already focused on subunit candidates, especially surface associated targets (reviewed by Baums 280 
et al.) (38), recent reports emphasize the ongoing challenges of matching candidates with 281 
promising measures of protection in mouse models and in vitro assays with in vivo survival 282 
outcomes in live challenged pigs (39). 283 
The five proteins identified are highly conserved and present in almost all strains of S. 284 
suis tested including probable non-virulent strains. Since these strains are normal colonizers of 285 
pigs, one might expect that antibodies against these proteins are already present in pigs on farm. 286 
There was reactivity to four of the proteins in serum collected from a convalescent pig infected 287 
with virulent S. suis (Figure 1); however, non-virulent strains are commensal microbes that could 288 
colonize without triggering a significant immune response. The diversity of antibody responses 289 
to these proteins in pigs naturally exposed to S. suis, with or without disease, might shed further 290 
light on their respective contribution to immune protection. Further studies will also be needed to 291 
evaluate the optimum approach to field application of these subunits as protective immunogens, 292 
including the potential for sow versus piglet immunization and the possibility of prior passive or 293 
active antibody interference. In addition, the reactivity of the sera from vaccinated pigs against 294 
several diverse S. suis strains commonly associated with disease in pigs may indicate a potential 295 
for cross-protection that will have to be confirmed through further challenge studies. 296 
 297 
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Materials and methods 298 
Bacterial strains, vectors, media and antibiotics used in the study. Bacterial strains 299 
and vectors used in this study are listed in Table 5. S. suis strains were routinely grown at 37 
o
C 300 
in Todd-Hewitt broth (Oxoid) supplemented with 0.2% yeast (Sigma) (THY) or on Columbia 301 
agar (Oxoid) containing 5% (v/v) defibrinated horse blood (TCS Bioscience) (CBA). E. coli 302 
strains were routinely grown at 37 
o
C on Luria Bertani (LB) agar plates or cultured in LB broth 303 
(Oxoid). E. coli strains expressing recombinant proteins were grown at 37 
o
C in 2YT broth (Life 304 
Technologies). Kanamycin (Sigma) at the concentration of 100 µg/ml was used to select E. coli 305 
transformants. All the strains were stored at -80 
o
C in 20% glycerol. 306 
S. suis (P1/7), a serotype 2 isolate from the blood of a pig with meningitis (40), was used 307 
for challenge and was grown on tryptic soy agar containing 5% sheep blood (Becton, Dickinson 308 
and Co.) at 37 
o
C overnight, scraped from the plates and resuspended in phosphate buffered 309 
saline (PBS) to an optical density of 0.42 at A600 to give an inoculum dose of 1 x 10
9
 cfu/ml. 310 
Each challenged pig received 1 ml per nostril (2 ml total). 311 
General molecular biology techniques. The genomic DNA of S. suis strains was 312 
isolated using MasterPure
TM
 Gram positive DNA purification kit (Epicentre Biotechnologies). 313 
Bacterial lysates of S. suis were prepared using Instagene™ Matrix, a Chelex-based resin (Bio-314 
Rad Laboratories Ltd.) according to the manufacturer’s instructions. The plasmid DNA samples 315 
were prepared using a QIAprep Spin Miniprep Kit (Qiagen) or a HiSpeed Plasmid Maxi Kit 316 
(Qiagen). Plasmids and genomic DNA were stored at -20 °C.  317 
The polymerase chain reactions (PCRs) for screening bacterial colonies were set up with 318 
Go Taq Green Master Mix (Promega Ltd.) according to the manufacturer’s instructions. The 319 
amplification conditions used were as follows: initial denaturation at 95 
o
C for 2 minutes 320 
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followed by 30 cycles of denaturation at 95 
o
C for 30 seconds, annealing at 60 
o
C for 30 seconds 321 
and extension at 72 
o
C for a period determined by the size of the PCR product (1 minute/kb), 322 
with a final extension step at 72 
o
C for 7 minutes.  323 
The PCR products used for cloning were amplified using Phusion® High Fidelity DNA 324 
polymerase (Thermo-Fisher Scientific) according to the manufacturer’s instructions. The 325 
reactions contained 100 ng of template DNA or 1-5 µl bacterial lysate, 200 µM of each dNTP 326 
(Bioline Ltd.), 0.5-1 µM of each primer (Sigma-Aldrich Ltd.), 1× PCR buffer, 1 unit of DNA 327 
polymerase and DMSO at a final concentration of 3% when required. The initial denaturation 328 
was done at 98 
o
C for 30 seconds followed by 30 cycles of denaturation at 98 
o
C for 10 seconds, 329 
annealing at appropriate temperatures for 30 seconds and extension at 72 
o
C for a period 330 
determined by the size of the PCR product (10-30s/kb). The final extension was done at 72 
o
C 331 
for 7 minutes.  332 
The primers used in this study are listed in Table 6. The primers were designed using 333 
Primer3web version 4.0.0 (http://primer3.ut.ee) and synthesized by Sigma-Aldrich Ltd. The 334 
primers were rehydrated with deionized water to a concentration of 100 µM on arrival and 335 
working stocks of 10 µM concentration were prepared. All primers were stored at -20 
o
C.  336 
The PCR products and DNA samples were analyzed by agarose gel electrophoresis. The 337 
agarose gels were visualized and photographed using the Gel Doc™ XR+ imaging system with 338 
Image Lab™ image acquisition and analysis software (Bio-Rad Laboratories Ltd.). 339 
 SDS-PAGE analyses were performed with whole cell lysates or purified proteins. Samples 340 
were diluted in equal volumes of 2X SDS sample buffer, heated at 70 
o
C for 10 minutes and run 341 
on 4-12% (v/v) Bis-Tris gels (Life Technologies) to confirm protein expression.  342 
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Selection of candidate vaccine proteins. A strategy of combining experimental 343 
functional genomics screening (IVOC with TraDIS) with in silico bioinformatics approaches was 344 
applied for selection of candidate vaccine proteins using a library generated in S. suis strain P1/7 345 
(13-17, 41). The selection consists of the following steps: (1) candidate fitness genes (defined as 346 
a gene that harbored at least one transposon insertion mutant with significant reduction in fitness 347 
in a swine respiratory epithelium IVOC system) were determined through previous functional 348 
genomics screening, (2) protein subcellular localization was predicted in silico with 349 
bioinformatics approaches using PSORTb (http://db.psort.org/) and LocateP 350 
(http://www.cmbi.ru.nl/locatep-db/cgi-bin/locatepdb.py) databases or based on literature 351 
mining to shortlist fitness genes encoding surface-associated proteins [(cell wall anchored or 352 
extracellular (lipid-anchored or secretory)], (3) proteins containing transmembrane domains in 353 
the middle of protein coding sequence were excluded, (4) in silico protein homology based 354 
searches to identify proteins with cross-protection potential: i.e. the presence of the protein from 355 
the S. suis P1/7 genome was used as a query in a BlastX search and we identified proteins 356 
present (80% identity over 80% of the length) in 459 publically available strains or in the 357 
majority of disease-associated strains (12), (5) a final pool with five potential candidate vaccine 358 
proteins were chosen whose potential to be applied as a cassette of subunit vaccine has not been 359 
previously published, patented or tested in pig protection studies. 360 
Cloning and expression of candidate vaccine proteins. Genes of interest were cloned 361 
from the genome of S. suis strain P1/7 excluding the signal sequences when present. Signal 362 
peptide cleavage sites of open reading frames (ORFs) were predicted using SignalP 363 
(http://www.cbs.dtu.dk/services/SignalP). The PCR products of candidate genes were cloned in 364 
to the pET-30 Ek/LIC vector (Merck Millipore) and fusion plasmids were transformed into E. 365 
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coli NovaBlue (Merck Millipore) according to the manufacturer’s instructions. The positive 366 
recombinants were confirmed by PCR and DNA sequencing and then transformed into E. coli 367 
BL21 (DE3) (Merck Millipore) for expression. Overnight culture of E. coli BL-21 (DE3) strains 368 
carrying the recombinant plasmids were used to inoculate fresh 1-6 L 2YT broth and grown to 369 
OD595nm 0.6 at 37 °C in broth supplemented with 100 µg/ml kanamycin, then induced with 1mM 370 
IPTG (isopropyl β-D-1-thiogalactopyranoside, Sigma) at 37 oC for 2, 4 and 24 hours. Protein 371 
expression was checked by SDS-PAGE using whole cell lysates. 372 
Purification of recombinant vaccine proteins. Recombinant proteins were purified 373 
from 1-6 L cultures grown in 2YT broth and induced with 1 mM IPTG for 2 to 4 hours. Cell 374 
pellets were washed once in PBS and centrifuged at 3,000 × g for 15 minutes. The cell pellets 375 
were resuspended in binding buffer (10 mM imidazole, 300 mM NaCl, 50 mM phosphate, 376 
pH:8.0) and sonicated on ice for 6 minutes. Appropriate amounts of Benzonase and rLysozyme 377 
(Novagen, Merck Millipore) were added to reduce the viscosity of the lysate and improve protein 378 
extraction efficiency. The lysates were first centrifuged at 3,000 × g for 10 minutes at 4 °C to 379 
pellet debris and the supernatants were subjected to further centrifugation at 75,000 × g for 1.5 380 
hours at 4 °C. Recombinant proteins were subjected to purifications by nickel His-Tag affinity 381 
chromatography, anion exchange chromatography, CHAP chromatography and gel filtration 382 
when appropriate. Target proteins were confirmed by peptide mass fingerprinting. Protein 383 
concentration was determined using spectrophotometry and purified proteins were stored at -80 384 
°C. 385 
 Immunoreactivity of the recombinant proteins with convalescent pig sera. 386 
Immunoreactivity against the purified recombinant proteins was tested using serum from a 387 
conventionally-reared pig experimentally infected with S. suis serotype 2. Naïve sera for a 388 
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control was a pool collected from Gottingen mini-pigs (Serolabs Ltd.), which were reared in a 389 
pathogen-free environment and not expected to have any antibodies against S. suis. The purified 390 
recombinant proteins were separated on 4-12% (v/v) Bis-Tris gels under denaturing conditions 391 
and transferred to PVDF membranes. The membranes were rinsed in Tris buffered saline (30 392 
mM tris base, 138 mM NaCl, 2.7 mM KCl, pH 8.0) with 0.05% Tween 20 (TBST) and then 393 
blocked with 2% casein in TBST, overnight at 4 
o
C. The pig sera (1:2000) were used as primary 394 
antibody and Horseradish-peroxidase (HRP) conjugated goat anti-pig (1:10000) (Sigma) was 395 
used as secondary antibody. The primary and secondary antibodies were diluted in 1% casein in 396 
TBST and membranes were probed at room temperature (RT) for 1-1.5 hours. The blots were 397 
then washed three times in TBST for 10 minutes at room temperature. The membranes were 398 
developed with Chemiluminescent substrate (Novex® ECL substrate reagent kit, Life 399 
Technologies) according to the manufacturer’s instructions. The ECL substrate treated 400 
membranes were exposed to X-ray film (Amersham Hyperfilm ECL, GE Healthcare 401 
Lifesciences) for a suitable duration and developed in an X-ray film developer. 402 
Vaccine protection study. The USDA-ARS-National Animal Disease Institutional 403 
Animal Care and Use Committee approved all animal work. Twenty-two, 5-week-old, 404 
Caesarean-derived, colostrum-deprived (CDCD) pigs were distributed into groups as follows 405 
(Table 3): group 1 pigs (6 pigs) were given a 2 ml dose of vaccine containing 250 µg protein (50 406 
µg per subunit) with 1ml of Addavax
TM
 emulsion (Squalene-based oil-in-water adjuvant- 407 
Invivogen), and 5 mg of Carbopol
®
-971 (Lubrizol Corporation) intramuscularly (IM) in the neck 408 
and a 2 ml dose of vaccine containing 500 µg protein (100 µg per subunit) and 500 µg of 409 
Polyethyleneimine (Sigma) intranasally (IN- 1 ml per nostril); group 2 pigs (6 pigs) were 410 
vaccinated similarly IN but in the 2 ml IM dose the proteins were mixed with Emulsigen
®
-D (oil-411 
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in-water emulsion with dimethyldioctadecylammonium bromide – MVP technologies) at a 1:5 412 
(v/v) mix; groups 3 and 4 were control groups given PBS mixed with the same adjuvants given 413 
to groups 1 and 2 respectively (3 pigs each); and group 5 was given PBS only (4 pigs). Pigs 414 
received a booster dose of the same respective formulation 2 weeks after priming, and 2 weeks 415 
after the boost pigs were challenged with 2 ml of 10
9
 CFU/ml S. suis P1/7 IN (1 ml per nare). 416 
Blood was collected on day 0 (prime) for serum, and days 14 (boost), 21 (one week post-boost) 417 
and 28 (challenge) for serum and peripheral blood mononuclear cells (PBMC) to evaluate 418 
vaccine immunogenicity. After challenge pigs were observed for clinical signs of disease 419 
(approximately every 4-5 hours except for an 8 hour overnight period), including lameness, 420 
lethargy, and neurological symptoms. If presentation was severe (such as neurologic 421 
involvement, severe lameness, or depression that resulted in recumbency with reluctance to 422 
stand) the pig was euthanized. Pigs not showing signs of disease or only transitory or mild signs 423 
of disease were euthanized 15 days post challenge. At necropsy nasal wash, swabs of serosa and 424 
hock joint (or other affected joint), cerebrospinal fluid (CSF), lung lavage, and a section of tonsil 425 
and spleen were collected for culture. Nasal turbinate, tonsil, lung, heart, kidney, liver, spleen, 426 
retropharyngeal lymph node, brain and synovium were collected for microscopic pathological 427 
examination. 428 
Evaluation of the humoral immune response to vaccination. Serum IgG titers to 429 
individual S. suis proteins and reactivity to inactivated P1/7 were determined using an indirect 430 
ELISA. Blood was collected into a BD Vacutainer Serum Separator Tube (SST) and serum 431 
isolated according to manufacturer’s recommendation (BD Pharmingen) with storage at -80 °C 432 
until used in assays. For evaluation of antibody titers to individual S. suis proteins Immulon-2 433 
plates were coated with 0.1 ml of each individual protein in 100 mM carbonate-bicarbonate 434 
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buffer (pH 9.6) overnight at 4 °C at the following concentrations: SSU1773 (1 µg/ml), SSU1355 435 
(2 µg/ml), SSU1915 (1 µg/ml), SSU0185 (1 µg/ml), SSU1215 (0.5 µg/ml). The next day, plates 436 
were blocked with 0.2 ml of blocking buffer [2% BSA in PBS tween (0.05% Tween-20; PBS-T)] 437 
for 2 hours at RT and then washed three times with PBS-T. Eleven, two-fold serial dilutions of 438 
serum (starting at 1:2000) collected from each pig were made in 1% BSA/PBS-T, transferred to 439 
the ELISA plate in duplicate and incubated at RT for 2 hours. Plates were washed and S. suis 440 
specific IgG detected by adding 0.1 ml of anti-porcine IgG conjugated to horseradish peroxidase 441 
(KPL, catalog 14-14-06, dilution 1:10,000) and incubating at RT for 1 hour. Plates were washed 442 
and TMB substrate added according to manufacturer’s recommendations (Life Technologies). 443 
After 15 minutes with substrate, 0.05 ml of stop solution (2N H2SO4) was added and optical 444 
density read at 450 nm with correction at 655 nm.  The resulting OD data were modeled as a 445 
nonlinear function of the Log10 dilution using Graph Pad Prism (La Jolla, CA) log (agonist) vs. 446 
response-variable slope four-parameter logistic model.  Endpoints were interpolated by using 4X 447 
the average OD of the day 0 sample of each respective pig serum as the cutoff.   448 
To determine whether serum IgG reacted with whole P1/7 S. suis bacteria, heat-449 
inactivated (HI) P1/7 was used as antigen in an indirect ELISA. To make antigen, a single P1/7 450 
colony was inoculated into 5 ml THB and incubated at 37 °C in 5% CO2 at 200 rpm for 451 
approximately 6 hours, at which time it had reached an OD=0.6 at Abs600. The bacteria were 452 
centrifuged at 4000 x g to pellet, media decanted and bacteria resuspended in 5 ml PBS. Bacteria 453 
were heat-inactivated (HI) by incubating the suspension in a water bath at 85 °C for 20 minutes. 454 
Inactivation was confirmed by plating 0.1 ml of the heat-inactivated preparation on blood agar 455 
plates and incubating the plates at 37 °C in 5% CO2. No growth was observed on the plate after 2 456 
days. Aliquots were stored frozen at -80 °C. Protein concentration of the HI P1/7 was determined 457 
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using BCA protein microtiter assay according to manufacturer’s recommendations (Pierce). 458 
Immulon-2 plates were coated with 0.1 ml of 7.5 µg/ml of HI P1/7 diluted in 100 mM carbonate-459 
bicarbonate buffer (pH 9.6). Serum samples collected on day 0 and day 28 from each pig were 460 
diluted 1:500 and used in the assay. P1/7-specific IgG was detected and the ELISA completed as 461 
described above for individual proteins. Data is reported as the OD at 450 nm with correction at 462 
655 nm. A checkerboard of HI P1/7 concentrations and a pool of sera from day 0 and day 28 was 463 
used to determine optimal ELISA conditions (data not shown). Similar techniques were used to 464 
evaluate IgG reactivity with a collection of other HI S. suis strains comprised of two randomly 465 
selected representatives of those serotypes most commonly associated with disease (1, 2, 1/2, 3 466 
and 14) (see Table 1), with bacteria reaching OD’s of 0.6 - 1.1 at 600 nm in the 6-8 hour culture 467 
period prior to HI (data not shown) and all HI S. suis coated at 7.5 g/ml for the ELISA. 468 
Evaluation of the cell-mediated immune response to vaccination. To evaluate 469 
induction of cell-mediated immunity following vaccination, ELISpot assays were performed to 470 
enumerate IFN-γ-secreting cells following in vitro stimulation with a pool of the vaccine 471 
proteins. Blood was collected by venipuncture into a BD Vacutainer Cell Preparation Tubes 472 
(CPT) with sodium citrate for isolation of PBMC using culture media as previously described 473 
(42). PBMC were enumerated and seeded at 2.5x10
5
 cells per well in the IFN-γ ELISpot plates in 474 
duplicate for each treatment. PBMC were stimulated with a protein pool in final volume of 0.25 475 
ml (1 µg/ml of each individual protein per well). Control wells received media alone or 476 
pokeweed mitogen (0.5 µg/ml). Approximately 18 hours after stimulation the ELISpot assay was 477 
completed according to manufacturer’s recommendations (R&D Systems, Minneapolis, MN).  478 
Spots were enumerated using a S5UV ImmunoSpot instrumentation and software (Cellular 479 
Technology Ltd., Shaker Heights, OH) and data analyzed using GraphPad Prism software (La 480 
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Jolla, CA). The count for duplicate wells for each treatment for each pig was determined and 481 
used to calculate the mean for each group.  482 
Cytokines produced by PBMCs collected on day 28 following restimulation with the 483 
protein pool were also measured. PBMC culture supernatants were collected 72 hours after 484 
restimulation with the protein pool or media-only and used to evaluate cytokine levels secreted 485 
by the cells. The amount of IFN-γ, TNF-α, IL-2, and IL-10 in the media was determined by 486 
multiplex cytokine ELISA according to manufacturer’s recommendations using provided 487 
recombinant proteins as standards to determine concentrations in the supernatants (Aushon 488 
Biosystems)   489 
Statistical Analysis. Survival analysis was performed using the product limit method of 490 
Kaplan and Meier, and comparing survival curves using the logrank test (GraphPad Prism, La 491 
Jolla, CA). Antibody titers were Log10 converted and a two-tailed student’s t-test was used to 492 
evaluate statistical differences between groups 1 and 2 for indicated comparisons, with a p-value 493 
<0.05 considered significant. One-way analysis of variance (ANOVA) with a Tukey’s multiple 494 
comparison post-test was performed to evaluate statistical differences between groups (p<0.05) 495 
for the number of IFN- secreting cells and cytokine production. Graph Prism software (version 496 
6.0) was used for statistical analysis. 497 
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Table 1. Characteristics of the five candidate vaccine proteins 661 
Antigen 
encoding 
genes 
Function/ortholog 
Range of 
TraDIS 
fitness 
scoresa 
Full length 
protein  
residues 
(AA) 
N-
terminal 
signal 
peptideb 
(AA) 
Protein 
subcellular 
localization 
predictionc 
Conserved 
Domain 
Fusion 
proteind 
AA / 
KDa 
SSU0185 
Putative tagatose-6-
phosphate aldose/ketose 
isomerase (AgaS) 
-4.66 to -
8.58 (3/3) 
389 / 
Extracellular 
(literature 
mining) 
/ 432 /47.4 
SSU1215 
Putative surface-anchored 
dipeptidase 
-0.90 to -
10.22 
(3/4) 
607 1-27 
Cell-wall 
anchored (in 
silico) 
LPSTG 
623 / 
67.4 
SSU1355 
Putative surface-anchored 
5'-nucleotidase 
-0.81 to -
8.23 (3/4) 
674 1-30 
Cell-wall 
anchored (in 
silico) 
LPNTG 
687 / 
74.1 
SSU1773 
Putative surface-anchored 
serine protease 
1.00 to -
8.7 4 (6/8) 
1692 1-40 
Cell-wall 
anchored (in 
silico) 
LPQTG 
1695 / 
187.4 
SSU1915 
Putative 
maltose/maltodextrin-
binding protein precursor 
(MalX) 
-5.03 to -
5.05 (2/2) 
419 / 
Lipid-anchored 
(in silico) 
/ 
462 / 
49.0 
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a 
TraDIS fitness scores were presented as log2 fold change of Output:Input determined by 662 
DESeq2 after normalisation. The fraction of significantly attenuated mutants in each gene is 663 
shown in parentheses, using the parameters: input read ≥ 500, P- value ≤ 0.05. 664 
b 
Genes encoding the surface proteins were cloned without the N-terminal signal peptides. 665 
c in silico protein subcellular localization predictions by PSORTb and LocateP 666 
d 
The amino acid residues and molecular weights of pET30 Ek/LIC fusion proteins were 667 
calculated including the protein tag generated from the vector (43 AA, 4.8KDa) and excluding 668 
the signal peptides if present. 669 
 670 
Table 2. Presence of the five immunogenic antigens in 459 isolates of S. suis 671 
Protein 
Presence in S. suis isolate collectiona 
No. of isolates in which 
protein is present 
Clinicalb              (292 
isolates) 
Non-clinicalc     
(134 isolates) 
Not Knownd                 
(33 isolates) 
SSU0185 459 100% 100% 100% 
SSU1215 452 99% 97% 94% 
SSU1355 459 100% 100% 100% 
SSU1773 450 98% 97% 100% 
SSU1915 458 100% 99% 100% 
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a 
The presence of the protein was investigated by taking the sequence of the protein from P1/7 672 
and using BlastX against the 459 genomes. If the protein had an 80% identity over 80% of the 673 
length, it was classified as present.  674 
b
Isolates recovered from either systemic sites in pigs with clinical signs and/or gross pathology 675 
consistent with S. suis infection (including meningitis, septicaemia and arthritis) or respiratory 676 
sites in the presence of gross lesions of pneumonia from the lung were classified as clinical.  677 
c
 Isolates from the tonsils or tracheo-bronchus of healthy pigs or pigs without any typical signs of 678 
S. suis infection but diagnosed with disease unrelated to S. suis (such as enteric disease or 679 
trauma) were classified as non-clinical. 680 
d
 Isolates for which there was insufficient information about the pigs sampled were classified as 681 
not known.  682 
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Table 3. Protein identities of the five subunit vaccine candidates in disease-associated S. suis 683 
serotype representatives
a
 684 
Strain ID  Serotype  SSU0185 SSU1215  SSU1355  SSU1773  SSU1915 
SS021
b
 1 100% 99% 100% 100% 100% 
SS045  1 100% 100% 100% 100% 100% 
SS100  1/2 100% 100% 100% 100% 100% 
SS043  1/2 98% 99% 99% 98% 100% 
SS002  2 100% 100% 100% 100% 100% 
SS008  2 98% 99% 99% 98% 100% 
SS053  3 98% 99% 99% 97% 100% 
SS084  3 98% 99% 99% 97% 100% 
SS062  4 97% 90% 99% 96% 97% 
SS079 4 88% 43% 75% NPc 85% 
SS018  7 98% 99% 99% 98% 99% 
SS024  7 98% 99% 99% 98% 99% 
SS068  8 98% 99% 99% 98% 100% 
SS091  8 98% 99% 99% 97% 100% 
SS015  9 97% 91% 96% 96% 97% 
SS088  9 97% 90% 96% 96% 97% 
SS078  10 96% 100% 95% 96% 97% 
SS063  14 100% 100% 100% 100% 100% 
SS077  14 100% 100% 100% 100% 100% 
SS097  16 98% 98% 97% 97% 98% 
SS037 22 88% 43% 73% NP 85% 
SS009  23 97% 91% 96% 96% 97% 
SS082  31 98% 92% 96% 97% 97% 
a
The panel contains 2 representatives (where possible) of disease associated serotypes. 685 
Respiratory isolates are selected where no other systemic isolate was available.  686 
b
Strains in bold also used in cross reactive ELISAs shown in Figure 6. 687 
c
NP = not present, if the protein had less than an 80% identity over 80% of the length, it was 688 
classified as not present.  689 
 o
n
 January 29, 2018 by LO
NDO
N SCHO
O
L O
F HYG
IENE & TRO
PICAL M
ED
http://iai.asm
.org/
D
ow
nloaded from
 
                                                                                                                                                     34 
 
Table 4. Experimental groups. 690 
Group Vaccine/Adjuvant/Route Challenge Number of Pigs 
Group 1 S. suis proteins/Polyethyleneimine/IN 
S. suis proteins/Carbopol
®
 & AddaVax
TM
/IM 
S. suis P1/7 6 
Group 2 S. suis proteins/ Polyethyleneimine/IN 
S. suis proteins/Emulsigen
®
D/IM 
S. suis P1/7 6 
Group 3 PBS/ Polyethyleneimine/IN 
PBS/ Carbopol
®
 & AddaVax
TM
/IM 
S. suis P1/7 3 
Group 4 PBS/ Polyethyleneimine/IN 
PBS/ Emulsigen
®
D/IM 
S. suis P1/7 3 
Group 5 PBS/none/IN 
PBS/none/IM 
S. suis P1/7 4 
IN = intransal; IM = intramuscular; PBS = phosphate buffered saline 691 
 692 
  693 
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Table 5. Bacterial strains and vectors used in this study. 694 
S. suis pig isolates Serotype Clinical associationa Tissue origin 
P1/7 2 SYS-BRAIN blood 
SS021  1  SYS-OTHER  joint/skin  
SS045  1  SYS-BRAIN  meninges  
SS100  1/2  SYS-BRAIN  brain  
SS043  1/2  RESP lung  
SS002  2  SYS-BRAIN  Brain  
SS008  2  SYS-OTHER  pericardial swab  
SS053  3  SYS-BRAIN  brain  
SS084  3  RESP lung  
SS062  4  SYS-BRAIN  brain  
SS079  4  SYS-BRAIN  brain  
SS018  7  SYS-OTHER  Lung/pericardium  
SS024  7  SYS-BRAIN  brain  
SS068  8  SYS-BRAIN  brain  
SS091  8  RESP-SD  lung  
SS015  9  SYS-BRAIN  brain  
SS088  9  SYS-OTHER  joint  
SS078  10  SYS-OTHER  joint  
SS063  14  SYS-OTHER  joint  
SS077  14  SYS-BRAIN  brain  
SS097  16  SYS-OTHER  spleen  
SS037  22  RESP  lung  
SS009  23  RESP  lung  
SS082  31  RESP-SD  lung  
E. coli strains and 
vector 
Application    
E. coli NovaBlue  E. coli  host for cloning  
E. coli BL21(DE3) E. coli  host for expressing  recombinant protein   
pET-30 Ek/LICb 
Vector for cloning,  expression and purification of target 
proteins  
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a 
Isolates recovered from systemic sites in pigs with clinical signs and/or gross pathology 695 
consistent with S. suis infection (including meningitis, septicaemia and arthritis) were classified 696 
as systemic (SYS), whereas those recovered from the lung in the presence of gross lesions of 697 
pneumonia were classified as respiratory (RESP). Isolates recovered from the lung of pigs with 698 
pneumonia but also with gross signs of systemic streptococcal-type disease were classified as 699 
RESP-SD. 700 
b
 The pET-30 Ek/LIC vector is designed for cloning and high-level expression of target proteins 701 
fused with the His•Tag® and S®Tag™ coding sequences that are cleavable with enterokinase 702 
(Ek) protease. The plasmid contains a strong T7lac promoter, an optimized RBS, the coding 703 
sequence for the Ek protease cleavage site (AspAspAspAspLys↓), and a multiple cloning site 704 
that contains restriction enzyme sites found in many other Novagen expression vectors to 705 
facilitate insert transfer. An optional C-terminal His•Tag coding sequence is compatible with 706 
purification, detection, and quantification.
 707 
  708 
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Table 6. Protein cloning primers used in this study. 709 
Primer ID Primer function  Sequence (5'-3') 
0185-4Fa 
Cloning primers for SSU0185 
GACGACGACAAGATGTTCCGTTTAGCAAAAGAAGAAC 
0185-1167R GAGGAGAAGCCCGGTTATTTTTCTAAAGGATGGATGA 
1915-4F 
Cloning primers for SSU1915 
GACGACGACAAGATGAAACACAATCTCCTTAAGAGCG 
1915-1257R GAGGAGAAGCCCGGTTAGTTGCTGTGTTTTTGAGCAA 
1215-82F 
Cloning primers for SSU1215 
GACGACGACAAGATGGGCTTTATTATTGGGAAAGG 
1215-1831R GAGGAGAAGCCCGGTTATTCTTTACTGGATTTTTTTC 
1355-91F 
Cloning primers for SSU1355 
GACGACGACAAGATGTTAGCTGTCCAAATTATGGGAG 
1355-2022R GAGGAGAAGCCCGGTTACTCCCCTTCCTTACGTCTCA 
1773-121F 
Cloning primers for SSU1773 
GACGACGACAAGATGGATACTAGTGGAGAAGGATTGG 
1773-5076R GAGGAGAAGCCCGGTTATTCTTTTCGCTTCAAATTTC 
a
Underlined nucleotides corresponded to the sequence extensions required for LIC compatibility 710 
with the pET-30 Ek/LIC cloning vector. 711 
 712 
  713 
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Figure 1. SDS-PAGE and Western blots of the five candidate vaccine proteins. The five 714 
candidate proteins were expressed in E. coli and purified as described in the Materials and 715 
Methods. The purified proteins were run on SDS-PAGE (A) and also transferred to membranes 716 
and probed with either serum from a pig experimentally infected with S. suis serotype 2 (B) or 717 
sera from pigs raised in a pathogen free environment as a negative control (C). 718 
 719 
Figure 2. IgG antibody titers among vaccinated pigs in groups 1 and 2 to the individual subunit 720 
proteins on day 14 (2 weeks after priming) and days 21 and 28 (1 and 2 weeks after boost). Pigs 721 
in Groups 1 and 2 (6 pigs each) were vaccinated with the 5 candidate proteins on days 0 and 14 722 
of the experiment. Both groups were given the 5 proteins intranasally with polyethyleneimine as 723 
adjuvant, in addition Group 1 pigs were given the 5 proteins intramuscularly with Addavax
TM
 724 
and Carbopol
®
 as adjuvant, while Group 2 pigs were given the 5 proteins intramuscularly with 725 
Emulsigen
®
-D as adjuvant. Titers were determined via indirect ELISA with plates coated with 726 
the individual proteins using two-fold serial dilutions of serum. The resulting OD data were 727 
modeled as a nonlinear function of the Log10 dilution using log (agonist) vs. response-variable 728 
slope four-parameter logistic model.  Endpoints were interpolated by using 2X the average OD 729 
of the day 0 sample for each respective pig as the cutoff.   730 
 731 
Figure 3. ELISpot data showing the number of IFN-γ secreting cells detected in PBMCs isolated 732 
from pigs in the indicated groups on days 14 (2 weeks after priming), 21, and 28 (1 and 2 weeks 733 
after boost). Pigs in Groups 1 and 2 (6 pigs each) were vaccinated with the 5 candidate proteins 734 
on days 0 and 14 of the experiment. Both groups were given the 5 proteins intranasally with 735 
polyethyleneimine as adjuvant, in addition Group 1 pigs were given the 5 proteins 736 
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intramuscularly with Addavax
TM
 and Carbopol
®
 as adjuvant, while Group 2 pigs were given the 737 
5 proteins intramuscularly with Emulsigen
®
-D as adjuvant. Groups 3-5 were control groups 738 
given the adjuvants (Groups 3 and 4, 3 pigs each) alone or PBS (Group 5, 4 pigs). PBMC 739 
collected on days 14, 21 and 28 were seeded at 2.5x10
5
 cells per well in duplicate and stimulated 740 
with a protein pool of the 5 candidate proteins. Control wells were stimulated with media alone 741 
or pokeweed mitogen (data not shown). The treatment group means and standard errors of the 742 
means are denoted. Statistically significant differences between groups are identified by an 743 
asterisk (P<0.05). 744 
 745 
Figure 4. Cytokines produced by PBMCs isolated from pigs in the indicated groups on day 28 (2 746 
weeks after boost). Pigs in Groups 1 and 2 (6 pigs each) were vaccinated with the 5 candidate 747 
proteins on days 0 and 14 of the experiment. Both groups were given the 5 proteins intranasally 748 
with polyethyleneimine as adjuvant, in addition Group 1 pigs were given the 5 proteins 749 
intramuscularly with Addavax
TM
 and Carbopol
®
 as adjuvant, while Group 2 pigs were given the 750 
5 proteins intramuscularly with Emulsigen
®
-D as adjuvant. Groups 3-5 were control groups 751 
given the adjuvants (Groups 3 and 4, 3 pigs each) alone or PBS (Group 5, 4 pigs). PBMCs 752 
collected on day 28 were stimulated in vitro with a pool of the 5 candidate proteins and the 753 
supernatants collected to evaluate cytokine levels secreted by the cells by multiplex cytokine 754 
ELISA. Data presented as box and dot plots with the mean cytokine concentration (pg/ml). 755 
Significantly different cytokine concentrations among groups are identified with different 756 
lettered superscripts (P<0.05).  757 
 758 
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Figure 5. Survival rates of pigs vaccinated with 5 subunit proteins with different adjuvant 759 
formulations (Groups 1 and 2) compared to pigs given adjuvant alone (Groups 3 and 4) or PBS 760 
(Group 5). Pigs in Groups 1 and 2 (6 pigs each) were vaccinated with the 5 candidate proteins on 761 
days 0 and 14 of the experiment. Both groups were given the 5 proteins intranasally with 762 
polyethyleneimine as adjuvant, in addition Group 1 pigs were given the 5 proteins 763 
intramuscularly with Addavax
TM
 and Carbopol
®
 as adjuvant, while Group 2 pigs were given the 764 
5 proteins intramuscularly with Emulsigen
®
-D as adjuvant. Groups 3-5 were control groups 765 
given the adjuvants alone (Groups 3 and 4, 3 pigs each) or PBS (Group 5, 4 pigs). 766 
 767 
Figure 6.  Cross reactive IgG antibody to whole S. suis bacteria of serotypes that commonly 768 
cause systemic disease from Group 1 and 2 pigs on day 28 (2 weeks after boost). Pigs in groups 769 
1 and 2 (6 pigs each) were vaccinated with the 5 candidate proteins on days 0 and 14 of the 770 
experiment. Both groups were given the 5 proteins intranasally with Polyethyleneimine as 771 
adjuvant, in addition group 1 pigs were given the 5 proteins intramuscularly with Addavax
TM
 and 772 
Carbopol
®
 as adjuvant, while group 2 pigs were given the 5 proteins intramuscularly with 773 
Emulsigen
®
-D as adjuvant. IgG reactivity was determined via indirect ELISA with plates coated 774 
with heat inactivated whole bacteria. Serum samples collected on day 28 from each pig were 775 
diluted 1:500 and used in the assay. Data is reported as the mean ± SEM optical density at 405 776 
nm. Bacterial strains are listed on the X-axis with serotype in parentheses. 777 
 778 
 779 
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